Price T Rowe Associates Inc Ultragenyx Pharmaceutical Inc. Call Options Transaction History
Price T Rowe Associates Inc
- $869 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding RARE
# of Institutions
333Shares Held
86.3MCall Options Held
520KPut Options Held
406K-
Vanguard Group Inc Valley Forge, PA10MShares$437 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.6MShares$244 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA5.12MShares$223 Million0.91% of portfolio
-
Alkeon Capital Management LLC New York, NY3.01MShares$131 Million0.29% of portfolio
-
State Street Corp Boston, MA2.66MShares$116 Million0.01% of portfolio
About Ultragenyx Pharmaceutical Inc.
- Ticker RARE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,036,896
- Market Cap $3.05B
- Description
- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...